Clinical Trial Update: PET Imaging of Ovarian Carcinoma With 18F-FSPG [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the PET imaging agent 18F-FSPG for ovarian, fallopian tube, and primary peritoneal cancers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• 18F-FSPG

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer | EARLY_Phase 1 | Status: WITHDRAWN